



## Synthesis and Evaluation of Novel Mannich Bases of N-methyl-3-phenyl-3-[4-trifluoromethyl) phenoxy] propan-1-amine (Fluoxetine)

Niaz Wali<sup>1\*</sup>, G. A. Miana<sup>1</sup> and Arif Hussain Shah<sup>2</sup>

<sup>1</sup>Riphah Institute of Pharmaceutical sciences, Riphah International University, Islamabad, Pakistan.

<sup>2</sup>Public Health Program, Faculty of Health and Well-being, Akamai University (AU), Hilo, Hawaii, USA.

### Authors' contributions

This work presented is the outcome of joint efforts of all authors. The study was designed by author GAM as a part of the assignments and tasks to be accomplished by the students working for M. Phil. degree program in Pharmaceutical Chemistry. The details were shared and discussed with author AHS. The work was done by author NW under close supervision and mentorship. All the data on chromatography, spectroscopy and biological assays of the newly synthesized compounds were presented by author NW, which was evaluated and approved in joint sessions. The final manuscript was prepared by mutual understanding of all the authors.

### Article Information

DOI: 10.9734/BJPR/2015/19068

Editor(s):

(1) Syed A. A. Rizvi, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, USA.

Reviewers:

(1) Fatma Kandemirli, Biomediacal Engineer, Kastamonu University, Turkey.

(2) Anonymous, Medical University of Vienna, Austria.

(3) Anonymous, India.

(4) Spasojevic Natasa, University of Belgrade, Belgrade, Serbia.

Complete Peer review History: <http://sciencedomain.org/review-history/10337>

Original Research Article

Received 23<sup>rd</sup> May 2015

Accepted 4<sup>th</sup> July 2015

Published 26<sup>th</sup> July 2015

### ABSTRACT

Three new Mannich bases of Fluoxetine (FA-1, FA-2, and FA-3) were synthesized and screened for their antidepressant activity through forced swim test. These new Mannich bases were synthesized in reflux condenser. Although none of the new compounds showed extra activity compare to its parent compound, nonetheless, they maintained antidepressant activity. The Mannich Bases were synthesized by attaching formaldehyde and different ketones to the secondary amine of fluoxetine at position-7. Their chemical structures have been confirmed by means of <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and MS data.

\*Corresponding author: Email: [niazokhan@gmail.com](mailto:niazokhan@gmail.com);

**Keywords:** Fluoxetine; mannich bases; antidepressant; carbonyl groups; forced swim test.

## 1. INTRODUCTION

Depression is a recurring, inveterate and possibly life-hazard illness victimizing about 20% of the world population. According to a World Health Organization (WHO) survey, it is one of the top ten causes of morbidity and mortality worldwide and 40–50% of the risks are genetic in nature. However, the particular genes that form the base for these risks are not yet known. Whilst the remaining 50–60% non genetic risks are not well defined too, generic views are confined to identifying early childhood trauma, emotional stress, physical illness, and even viral infections as the possible causatives. Most of the experts agree on categorizing depression as a syndrome and not a disease [1-4]. Currently effective antidepressant drugs are available but their main problem is severe side effects and thus about 70 percent patients using antidepressants discontinue them pre-maturely resulting in severe withdrawal effects [5-7]. Fluoxetine ( $C_{17}H_{18}F_3NO$ ) which is an early member of a newer class of antidepressant drugs commonly known as selective serotonin-reuptake inhibitors (SSRIs), got approval as a drug for the treatment of depression from FDA on 29 December 1987 [8]. It is in common use as a treatment for major depressive disorders (including pediatric depression), obsessive-compulsive disorder, bulimia nervosa and panic disorder but in the meantime it also possess severe side effects including sexual dysfunction, anorgasmia, delayed ejaculation, decreased libido, gastrointestinal disturbances, anxiety, sedation, nightmares and insomnia as well as suicidal attempts. These side effects causing the discontinuation of fluoxetine therapy. Due to these reasons, a greater need for faster acting, safer and more effective drugs for depression has always been felt [9-14].

Mannich reaction could be very helpful for synthesizing new effective drugs. The amino alkylation of CH-acidic compounds was explained by many chemists at the advent of 19<sup>th</sup> century; however, it was Professor Carl Mannich who for the first time recognized the significance of this reaction and deduced its mechanism resulting in this reaction being labeled after him. Mannich reaction is one of the most significant C-C bond forming reaction and has been used as a classical method for the preparation of Beta amino ketones and aldehydes which are called 'Mannich Bases'. Mannich bases are synthetic

building blocks, which can easily be converted into a range of useful and valuable derivatives. In essence, it is a condensation reaction where amino alkylation of the acidic proton occurs just next to the carbonyl group with aldehydes (mostly formaldehyde) and amines either primary or secondary which result in  $\beta$ -amino-carbonyl compound (Mannich Base). Mannich reaction plays an important role in pharmaceutical chemistry and it is amongst the commonly used reaction in the preparation of several drug products, therefore we decided to use this reaction on fluoxetine [15-19].

## 2. EXPERIMENTAL

### 2.1 Materials and Methods

Fluoxetine was gifted by Wilson Pharmaceuticals Islamabad, Pakistan in its standard packing. All the chemicals and solvents used in this research were analytical grade, dried and purified before use. Gallen Kamp apparatus was used for recording the melting points through capillary method. The compounds were purified by recrystallization technique in suitable solvents. Reactions were performed in reflux condensers; the progresses of reactions were monitored through Thin Layer Chromatography (TLC) on silica Gel Plates GF-254 (Macherey-Nagel, Germany) and were visualized by using ultraviolet light at 254 nm and 366 nm on HP-UVIS Desaga (Heidelberg, Germany). Nuclear Magnetic Resonance spectra were recorded on AVANCE Spectrophotometer AV 300. Solvent used for NMR analysis was of spectroscopy grade Dimethyl Sulfoxide (DMSO). Chemical shifts are given in parts per million (ppm), and tetramethylsilane (TMS) was used as internal standard. Mass spectra were recorded by using JEOL JMS 600-H system high resolution Mass spectrometry.

### 2.2 General Procedure

Equimolar fluoxetine and paraformaldehyde were dissolved separately in 10 ml ethanol. Both solutions were mixed and kept on reflux condenser with gentle heating and stirring for 30 min. Ketone was added then to the reaction mixture and refluxed. Progress of reaction was monitored through TLC. After completion, the mixture was precipitated by cooling, the precipitate was filtered, washed and

recrystallized to obtain pure product. The structure of each compound is given in Fig. 1-3.

### 2.2.1 Synthesis of 4-(methyl(3-Phenyl-3-(4(trifluoromethyl)phenoxy)propyl)amino)butane-2-one (FA-1)

Fluoxetine 2.78 g, 9 mmoles reacted with paraformaldehyde (9 mmoles) in ethanol absolute (10 ml) for 30 min, half pellet of NaOH was added to facilitate the solubility of paraformaldehyde and the mixture was placed on reflux condenser, then acetone (9 mmoles) was added to the reaction mixture and refluxed at 75°C for 12 hrs. Progress and purity were checked through TLC (Methanol: Chloroform: 25%Ammonia=43:43:14). Finally the mixture was kept in refrigerator overnight (8 hrs) to get precipitate, the precipitate was then filtered through whatman filter paper, washed with ethanol and recrystallized in hot ethanol resulted in final crystals.

#### 2.2.1.1 Product

Black sticky crystals; Melting Point=145°C; Molecular Formula=C<sub>21</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>2</sub>; Molecular Weight: 379.41 g/mole; %Yield=75%.




Fig. 1. Compound FA-1

The molecular ion peak of m/z 379.1 confirmed that the Mannich base has been formed. While the Proton NMR peak at C-16 was 3.35 ppm which gave strong evidence for Mannich Base as no other peak comes in this range and also the peak at C-17 was 2.08 ppm and C-19 at 2.07 ppm which further strengthened the evidence.

<sup>1</sup>H NMR: (d<sub>6</sub>-DMSO, 300MHz) δ: 1.90 (s, 3H); 2.24 (d, 2H); 2.11 (t, 2H); 5.51 (d, 1H); 7.03 (s, 1H); 7.52 (s, 1H); 7.55 (s, 1H); 7.06 (s, 1H); 7.37 (s, 1H); 7.35 (d, 1H); 7.26 (d, 1H); 7.33 (d, 1H); 7.39 (s, 1H); 3.35 (d, 2H); 2.08 (d, 2H); 2.07 (s, 3H).

<sup>13</sup>C NMR; DMSO (39.75); 30.12, 32.33, 43.17, 47.59, 53.14, 77.47, 115.19, 124.10, 128.26, 141.12, 160.63, 202.94 (see Table 1)

EIMS m/z (%): 379.41, 58.0, 72.0, 91.0, 104.0, 117.0, 135.0, 176.0, 218.0, 251.0, 309.0, 322.1, 337.0, 365.1, 379.1

Table 1. <sup>1</sup>H NMR and <sup>13</sup>C NMR data for compound FA-1

Carbon number	<sup>1</sup> H NMR data	<sup>13</sup> C NMR data
N-1	1.905	47.59
C-2	2.241	52.85
C-3	2.111	32.33
C-4	5.514	77.47
C-5	-----	160.63
C-6	7.039	114.90
C-7	7.525	126.77
C-8	-----	124.10
C-9	7.547	126.80
C-10	7.060	115.19
C-11	-----	125.99
C-12	-----	141.12
C-13	7.375	128.26
C-14	7.352	128.77
C-15	7.265	127.62
C-16	3.354	53.14
C-17	2.089	43.17
C-18	-----	202.94
C-19	2.074	30.12

4-(methyl(3-Phenyl-3-(4(trifluoromethyl)phenoxy)propyl)amino)butane-2-one (FA-1)

### 2.2.2 Synthesis of 3-(Methyl (3-Phenyl-3(4-trifluoromethyl)Phenoxy)Propylamino)1-Phenylpropan-1-one (FA-2)

Fluoxetine 2.78 g, 9 mmoles reacted with paraformaldehyde (9 mmoles) in ethanol absolute (10 ml) for 30 min, half pellet of NaOH was added to facilitate the solubility of paraformaldehyde and the mixture was placed on reflux condenser, then acetophenone(9 mmoles) was added to the reaction mixture and refluxed at 75C for 12 hrs. Progress and purity were checked through TLC (Methanol: Chloroform: 25%Ammonia=43:43:14). Finally the mixture was kept in refrigerator overnight (8 hrs) to get precipitate, the precipitate was then filtered through Whatman filter paper, washed with ethanol and recrystallized in hot ethanol resulted in final crystals.

The results of reaction are given in Scheme 1 <sup>1</sup>H NMR, C-13 NMR, and MS data for each compound is shown in Tables 1-4; & spectra for each compound are added for ready reference.

### 2.2.2.1 Product

Light yellowish crystals; Melting Point=260C°; Molecular Formula=C<sub>26</sub>H<sub>26</sub>F<sub>3</sub>NO<sub>2</sub>; Molecular Weight=441.48 g/mole; %Yield=77%.




Fig. 2. Compound FA-2

The molecular ion peak of m/z 440.3 confirmed that Mannich base has been formed. Whilst the Proton NMR peak at C-16 was 3.38 ppm which gave strong evidence for Mannich Base as no other peak comes in this range and also the peak at C-17 was 3.62 ppm which further strengthened the evidence.

<sup>1</sup>H NMR: (d<sub>6</sub>-DMSO, 300MHz) δ: 2.02 (s, 3H); 2.22 (d, 2H); 2.06 (t, 2H); 4.03 (d, 1H); 7.46 (s, 1H); 7.54 (s, 1H); 7.57 (s, 1H); 7.48 (s, 1H); 7.38 (s, 1H); 7.32 (d, 1H); 7.30 (d, 1H); 7.34 (d, 1H); 7.40 (s, 1H); 3.38 (d, 2H); 3.62 (d, 2H); 7.93 (s, 1H); 7.69 (d, 1H); 7.60 (d, 1H); 7.63 (d, 1H); 7.86 (s, 1H).

<sup>13</sup>C NMR; DMSO (39.70); 30.27, 37.91, 40.89, 52.81, 54.63, 77.46, 126.0, 127.43, 128.38, 135.21, 161.25, 202.12 (see Table 2)

EIMS m/z (%): 441.48, 51.0, 77.0, 105.0, 133.0, 171.1, 199.1, 233.0, 273.0, 291.1, 303.0, 335.1, 378.0, 408.0, 423.1, 440.3

### 2.2.3 Synthesis of 2-((Methyl(3-Phenyl-3(4-trifluoromethyl)Phenoxy)Propyl) amino) methyl) Cyclohexanone (FA-3)

Fluoxetine 2.78 g, 9 mmoles reacted with paraformaldehyde (9 mmoles) in ethanol absolute (10ml) for 30 min, half pellet of NaOH was added to facilitate the solubility of paraformaldehyde and the mixture was placed on reflux condenser, then cyclohexanone (9 mmoles) was added to the reaction mixture and refluxed at 75C for 12hrs. Progress and purity were checked through TLC (Methanol: Chloroform: 25% Ammonia=43:43:14). Finally the mixture was kept in refrigerator overnight (8hrs) to get precipitate, the precipitate was then

filtered through Whatman filter paper, washed with ethanol and recrystallized in hot ethanol which resulted in final crystals.

Table 2. <sup>1</sup>H NMR and <sup>13</sup>CNMR data for compound FA-2

Carbon number	<sup>1</sup> H NMR data	<sup>13</sup> C NMR data
N-1	2.027	40.89
C-2	2.225	52.81
C-3	2.060	30.27
C-4	4.039	77.46
C-5	-----	161.25
C-6	7.465	126.00
C-7	7.546	127.99
C-8	-----	127.62
C-9	7.572	127.83
C-10	7.489	126.77
C-11	-----	127.43
C-12	-----	135.46
C-13	7.387	128.26
C-14	7.327	128.56
C-15	7.309	127.77
C-16	3.385	54.63
C-17	3.623	37.91
C-18	-----	202.12
C-19	-----	135.24
C-20	7.932	128.82
C-21	7.699	128.74
C-22	7.601	133.23
C-23	7.637	128.66
C-24	7.865	128.77

3-(Methyl(3-Phenyl-3(4-trifluoromethyl)Phenoxy) Propylamino)1-Phenylpropan-1-one (FA-2)

### 2.2.3.1 Product

Off white crystals; Melting Point=130C°; Molecular Formula=C<sub>24</sub>H<sub>28</sub>F<sub>3</sub>NO<sub>2</sub>; Molecular Weight: 419.47 g/mole; %Yield=72%.




Fig. 3. Compound FA-3

The molecular ion peak of m/z 419.3 confirmed that Mannich base has been formed. While the Proton NMR peak at C-16 was 3.15 ppm which gave strong evidence for Mannich Base as no other peak comes in this range and also the peak

of C-17, C-19, C-20, C-21, C-22 were respectively at 2.19, 2.20, 2.08, 2.00, 2.06 ppm. The free proton 'NH' of fluoxetine is also a target.

**Table 3. <sup>1</sup>H NMR and <sup>13</sup>C NMR data for FA-3**

Carbon number	<sup>1</sup> H NMR data	<sup>13</sup> C NMR data
N-1	2.107	42.21
C-2	2.243	53.89
C-3	2.226	31.50
C-4	4.791	77.42
C-5	-----	160.80
C-6	7.542	115.98
C-7	7.615	125.21
C-8	-----	120.89
C-9	7.608	125.96
C-10	7.528	116.10
C-11	-----	123.71
C-12	-----	141.13
C-13	7.410	127.16
C-14	7.348	128.57
C-15	7.332	126.76
C-16	3.157	58.48
C-17	2.195	48.57
C-18	-----	210.46
C-19	2.204	42.15
C-20	2.082	28.61
C-21	2.009	24.96
C-22	2.068	31.66

*2-((Methyl(3-Phenyl-3(4-trifluoromethyl)Phenoxy) Propyl)amino)methyl)Cyclohexanone(FA-3)*

<sup>1</sup>H NMR: (d6-DMSO, 300MHz) δ: 2.10 (s, 3H); 2.24 (d, 2H); 2.2 (t, 2H); 4.79(d, 1H); 7.54 (s, 1H); 7.61 (s, 1H); 7.60 (s, 1H); 7.52 (s, 1H); 7.41 (s, 1H); 7.34 (d, 1H); 7.33 (d, 1H); 7.38 (d, 1H); 7.45 (s, 1H); 3.15 (d, 2H); 2.19 (m,2H); 2.20 (d,2H); 2.08 (m, 2H); 2.00 (m, 2H); 7.06 (m, 2H).

<sup>13</sup>C NMR; DMSO (39.75) 24.96, 31.50, 42.21, 48.57, 53.89, 58.48, 77.42, 116.10, 123.71, 125.96, 128.97, 141.13, 160.80, 210.46 (see Table 3)

EIMS m/z (%): 419.47, 44.0, 58.0, 91.0, 110.0, 148.0, 174.9, 217.9, 232.0, 276.1, 309.0, 321.9, 338.1, 352.1, 367.1, 386.1, 419.3.

### 3. RESULTS AND DISCUSSION

The free proton 'NH' of fluoxetine (Scheme: 1) is a potential point for synthesizing Mannich bases. In this present research work three novel Mannich bases (Fig. 1: FA-1, Fig. 2: FA-2, and Fig. 3: FA-3) were synthesized by reacting


fluoxetine, paraformaldehyde with different ketones i.e. Acetone, Acetophenone and Cyclohexanone by using the standard procedure. The synthesized compound's purity was checked by TLC (Thin layer chromatography) on silica gel plates which gave a single spot, confirming purity of the product. The chemical structure of the compounds was determined by [1] H-NMR, [13] C-NMR, and Mass spectroscopy and finally antidepressant activity was performed on mice using Forced Swim Test (FST).

### 3.1 Antidepressant Activity of New Compounds in Mice

#### 3.1.1 Procedure


The antidepressant activity of test samples was conducted using the forced swim test (FST). This test was based on stressful stimulus in which mice were put in water-jar about 25cm long and filled with water up to 10cm. The mice tried to escape by swimming and climbing from water jar but after a certain time it started floating on the surface of water without any further endeavor to escape, the situation being known as immobility. This condition could be described as "behavioral despair", where the animal loses hope to escape the stressful environment. So by administering antidepressant drugs, the immobility time will decrease. This immobility time is considered as an attribute of antidepressant effect. Total 48 albino mice with body weights between 20-25 g were divided into 08 groups each consisting of 6 mice. All these mice were subjected to daily treatment for a period of 14 days. On 14<sup>th</sup> day, instantly after intraperitoneal administration, each animal was separately allowed to swim freely in a transparent glass vessel (25 cm high, 10 cm diameter) filled with 10 cm of water at room temperature for a period of 05 minutes, as a pre test session, without recording any parameters. After 24 hours, forced swim test was performed in the same cylindrical vessel for 05 minutes [20]. The results of FST for Group 1-8 are presented in Table 4. The standard and treatment groups are explained as follows:

- Group 1- Negative control (10 ml/kg, vehicle)
- Group 2- FA-1- 10 mg/kg
- Group 3- FA-1- 20 mg/kg
- Group 4- FA-2- 10 mg/kg
- Group 5- FA-2- 20 mg/kg
- Group 6- FA-3- 10 mg/kg
- Group 7- FA-3- 20 mg/kg
- Group 8- Fluoxetine -10 mg/kg.




**Scheme 1. Reaction of fluoxetine with different ketones resulting in Mannich bases.**

NIAZ WALI/DR, G.A MIANA/FA-1/RIPS ISLAMBAD/



**<sup>1</sup>H NMR spectrum of compound FA-1**

NIAZ WALI/DR, G.A MIANA/FA-2/RIPS ISLAMBAD/



AVANCE 400  
LAB NO 117


```

NAME      june10-14
EXPNO     8
PROCNO    1
Date_     20140610
Time      11.12
INSTRUM   spect
PROBHD    5 mm DUL 13C-1
PULPROG   zg30
TD         32768
SOLVENT   DMSO
NS         64
DS         0
SWH        8012.820 Hz
FIDRES     0.244532 Hz
AQ         2.0447731 sec
RG         2048
DW         62.400 usec
DE         6.50 usec
TE         300.0 K
D1         2.00000000 sec
TDO        1

===== CHANNEL f1 =====
NUC1      1H
P1         10.20 usec
PL1        0.00 dB
SF01      400.1332010 MHz
SI         16384
SF         400.1300064 MHz
WDW        EM
SSB        0
LB         0.30 Hz
GB         0
PC         1.00
    
```

<sup>1</sup>H NMR spectrum of compound FA-2

NIAZ WALI/DR, G.A MIANA/FA-3/RIPS ISLAMBAD/



AVANCE 400  
LAB NO 117


```

NAME      june05-14
EXPNO     8
PROCNO    1
Date_     20140605
Time      12.05
INSTRUM   spect
PROBHD    5 mm DUL 13C-1
PULPROG   zg30
TD         32768
SOLVENT   DMSO
NS         128
DS         0
SWH        8012.820 Hz
FIDRES     0.244532 Hz
AQ         2.0447731 sec
RG         2048
DW         62.400 usec
DE         6.50 usec
TE         300.0 K
D1         1.50000000 sec
TDO        1

===== CHANNEL f1 =====
NUC1      1H
P1         10.20 usec
PL1        0.00 dB
SF01      400.1332010 MHz
SI         16384
SF         400.1300064 MHz
WDW        EM
SSB        0
LB         0.30 Hz
GB         0
PC         1.00
    
```

<sup>1</sup>H NMR spectrum of compound FA-3

NIAZ WALI/DR,G.A MIANA/FA-1/RIPS ISLAMBAD/  
BB/



AVANCE 400  
LAB NO 117

```


NAME      june09-14
EXPNO    5
PROCNO   1
Date_    20140609
Time     12.58
INSTRUM  spect
PROBHD   5 mm DUL 13C-1
PULPROG  zgpg
TD       32768
SOLVENT  DMSO
NS       18432
DS       2
SWH      24154.590 Hz
FIDRES   0.737140 Hz
AQ       0.6783476 sec
RG       32768
DW       20.700 usec
DE       6.50 usec
TE       300.0 K
D1       1.50000000 sec
D11      0.03000000 sec
TD0      18

===== CHANNEL f1 =====
NUC1     13C
P1       8.10 usec
PL1      7.00 dB
SFO1     100.6243395 MHz

===== CHANNEL f2 =====
CPDPRG2  waltz16
NUC2     1H
PCPD2    80.00 usec
PL2      0.00 dB
PL12     20.00 dB
PL13     22.00 dB
SFO2     400.1324008 MHz
SI       16384
SF       100.6128161 MHz
WDW      EM
SSB      0
LB       1.50 Hz
GB       0
PC       1.00
    
```

**C-13 NMR spectrum of compound FA-1**

NIAZ WALI/DR,G.A MIANA/FA-2/RIPS ISLAMBAD/  
BB/



AVANCE 400  
LAB NO 117

```


NAME      june10-14
EXPNO    9
PROCNO   1
Date_    20140610
Time     11.50
INSTRUM  spect
PROBHD   5 mm DUL 13C-1
PULPROG  zgpg
TD       32768
SOLVENT  DMSO
NS       18432
DS       2
SWH      24154.590 Hz
FIDRES   0.737140 Hz
AQ       0.6783476 sec
RG       32768
DW       20.700 usec
DE       6.50 usec
TE       300.0 K
D1       1.50000000 sec
D11      0.03000000 sec
TD0      18

===== CHANNEL f1 =====
NUC1     13C
P1       8.10 usec
PL1      7.00 dB
SFO1     100.6243395 MHz

===== CHANNEL f2 =====
CPDPRG2  waltz16
NUC2     1H
PCPD2    80.00 usec
PL2      0.00 dB
PL12     20.00 dB
PL13     22.00 dB
SFO2     400.1324008 MHz
SI       16384
SF       100.6128161 MHz
WDW      EM
SSB      0
LB       1.50 Hz
GB       0
PC       1.00
    
```

**C-13 NMR spectrum of compound FA-2**






C-13 NMR spectrum of compound FA-3

ICCBS-HEJ[LAB-104]  
6/2/2014

*Dr. Moina*

Page 1

File: FA-1 Date Run: 06-02-2014 (Time Run: 15:59:07)  
Sample: NIAZ WALI / DR. GA. MIANA / RIPS- ISLAMABAD.  
Instrument: JEOL JMS 600-H  
Inlet: My Inlet Ionization mode: EI+




Mass spectrum of compound FA-1

ICCBS-HEJ[LAB-104]  
6/2/2014

Page 1

File: FA-2- Date Run: 06-02-2014 (Time Run: 15:43:04)  
Sample: NIAZ WALI / DR. GA. MIANA / RIPS- ISLAMABAD.  
Instrument: JEOL JMS 600-H  
Inlet: My Inlet Ionization mode: EI+




Mass spectrum of compound FA-2

ICCBS-HEJ[LAB-104]  
6/2/2014

Page 1

File: FA-3 Date Run: 06-02-2014 (Time Run: 14:54:36)  
Sample: NIAZ WALI / DR. GA. MIANA / RIPS- ISLAMABAD.  
Instrument: JEOL JMS 600-H  
Inlet: My Inlet Ionization mode: EI+



Mass spectrum of compound FA-3

**Table 4. Antidepressant effect of compounds on duration of immobility, climbing and swimming of mice in forced swimming test (FST)**

Treatment (mg/kg)	Treatment (mg/kg)	Immobility (second)	Climbing (second)	Swimming (second)
Control	-	107.41±3.78	93.18± 4.92	98.61±3.27
FA-1	10	96.20±3.38	98.21±2.34	101.73±2.69
FA-1	20	92.47±2.09*	102.41±2.14*	107.52±3.08
FA-2	10	99.73±4.05	100.87±3.63	102.64±2.17
FA-2	20	93.97±3.65*	101.54±2.77*	105.97±2.56
FA-3	10	104.34±3.79	94.48±3.18	100.86±3.52
FA-3	20	100.22±2.61	99.04±2.56*	102.72±2.79
Fluoxetine	10	77.93±1.28**	106.71±2.14**	117.03±3.27

Statistical significance \* $P < 0.05$  and \*\* $P < 0.01$

#### 4. DISCUSSION AND CONCLUSION

Mannich bases of antidepressant fluoxetine (Selective serotonin reuptake inhibitor) were synthesized in reflux condenser by using paraformaldehyde and different ketones like acetone, acetophenone, cyclohexanone. Percentage yield of all Mannich bases (FA-1, FA-2, and FA-3) was good i.e. 75%, 77% and 72% respectively. Antidepressant activity was performed by adopting the standard procedure of forced swim test and recorded the different measures of depression like Swimming (Active movements of extremities and circling in the cylinder), Climbing/Trashing (Active upward directed movements of forelimbs on the container wall) and Immobility (floating in water without swimming i.e. mice did not attempt to escape except the movement which was necessary for its head to keep it above the water) were recorded as a measure of depression. Although none of the new compound showed extra activity compared to its parent compound nonetheless, they maintained antidepressant activity.

#### CONSENT

It is not applicable.

#### ETHICAL APPROVAL

All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the animal house ethics committee, Rifah University, Islamabad, Pakistan.

#### ACKNOWLEDGEMENT

The authors are thankful to Wilson Pharmaceuticals Islamabad, Pakistan for the supply of Fluoxetine in its standard packing which was used in the current experiment as a reference.

#### COMPETING INTERESTS

The work presented is for academic affairs. The authors have no conflict of interest or any competing interest with any institution or industry or organization. The authors have nothing to declare.

#### REFERENCES

1. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. *Nature Med.* 2001;7:541-547.
2. Nestler EJ, et al. Neurobiology of depression. *Neuron.* 2002;34:13–25.
3. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. *Psychosom. Med.* 67 Supplement. 2005;1:S26-S28.
4. Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. *Am. J. Psychiatry.* 2004; 161:195–216.
5. Cohen JB, Wilcox C. Comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder. *J Clin Psychiatry.* 1985;46:26–31.
6. Lin EH, Korff VM, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. *Med. Care.* 1995;33:67-74.

7. Zajecka JM. Clinical issues in long term treatment with antidepressants. *J Clin Psychiatry*. 2000;61:20–25.
8. Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride prozac. *Nat Rev Drug Discov*. 2005;4:764-74.
9. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: Beyond monoamines. *Nature Reviews Neuroscience*. 2006;7:137-151.
10. Breggin PR. Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs). *Int. Jour. of Risk & Safety in Med*. 2003/2004;16:31–49.
11. Clayton AH, Pradko AF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. *J Clin Psychiatry*. 2002;63:357–366.
12. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. *Ann. Clin. Psychiatry*. 2002;14(3):175-82.
13. Richelson E, Masand PS, Gupta S. Pharmacology of antidepressants. and Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. *Ann Clin Psychiatry*. 2002; 14:175–182.
14. Jick H, Kaye J, Jick S. Antidepressants and the risk of suicidal behaviors. *JAMA*. 2004;292:338–343.
15. Tramontini M, Angiolini L. Mannich-bases, chemistry and uses. CRC, Boca Raton, FL. 1994;261.
16. Tramontini M, Angiolini L, Ghedeni N. Mannich bases in polymer chemistry. A Review. *Polymer* 1988;29:771-788; and *Tetrahedron*. 1990;46:1791-1837.
17. Reich BE, Blicke FF. Die Mannich reaction. Springer, Berlin, Org. React (NY). 1959;1:303.
18. Dimmock JR, Raghavan SK, Logan BM, Bigam GE. Antileukemic evaluation of some Mannich bases derived from 2-arylidene-1,3-diketones. *Eur J Med Chem*. 1983;18:248–254.
19. Dimmock JR, Sidhu KK, Chen M, Reid, RS, Allen TM, Kao GY, Truitt GA. Evaluation of some Mannich bases of cycloalkanones and related compounds for cytotoxic activity. *Eur. J. Med. Chem*. 1993;28:313-322.
20. Mora S, Millán R, Lungenstrass H, Díaz-Véliz G, Morán JA, Herrera-Ruiz M, Tortoriello J. The hydroalcoholic extract of *Salvia elegans* induces anxiolytic-and antidepressant-like effects in rats. *J. Ethnopharmacology*. 2006;106:76-81.

© 2015 Wali et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:  
<http://sciencedomain.org/review-history/10337>